Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635024 · ClinicalTrials.gov registry record · Phase 2
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00635024: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00635024 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635024, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Anti-thymocyte globulin may also make cancer cells more sensitive to melphalan. Giving anti-thymocyte globulin together with melphalan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with melphalan works in treating patients with relapsed multiple myeloma.
Interventions
- DRUG melphalan
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635024
The ClinicalTrials.gov registry entry for NCT00635024 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00635024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635024 about?
NCT00635024 is a clinical study titled "Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma". RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping...
What is the current status of trial NCT00635024?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00635024?
The interventions under investigation include: melphalan (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00635024?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.